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ABSTRACT 
AIM: To explore the clinical impact and its molecular regulation on uterine leiomyomas  
in preoperative treatment with mifepristone, a progesterone receptor modulator (PRM).  
BACKGROUND: Uterine leiomyomas are highly prevalent in fertile women, increasing with 
age up to 35-50 % in a population approaching the age of 50. These most often benign tumors, 
frequently cause menorrhagia, and may interfere with fertility and the outcome of pregnancy. 
Progesterone and estrogen have a role in leiomyoma growth regulation, as well as in 
endometrial and breast cell proliferation and the development of endometrial and breast 
cancer. The objective of the current project was to study the effect of mifepristone on 
leiomyoma growth, as well as on cell proliferation in human endometrial and breast tissue in 
premenopausal women.  
METHODS: Thirty premenopausal women scheduled for surgical treatment due to uterine 
leiomyoma were randomized to either 50 mg mifepristone or non active treatment every other 
day, for 12 weeks before surgical intervention. Uterine and leiomyoma blood flow and 
leiomyoma volume were measured once a month until surgery. Endometrial biopsies were 
obtained and analyzed before and at end of treatment. Breast biopsies were assessed at 
baseline and at the end of the study for the expression of Ki-67 by immunocytochemical 
analysis in order to evaluate mammary epithelial cell proliferation. On surgery biopsies were 
collected from the periphery of the dominant leiomyoma. In order to investigate the gene 
expression leading to volume change in myoma, microarray analysis followed by Real time 
PCR analysis was performed. The degree of apoptosis was studied by TUNEL. Functional 
studies using primary cell cultures from fresh and untreated leiomyoma biopsies were 
performed to investigate the antiglucocorticoid response of mifepristone in the Integrin 
pathway. 
RESULTS: There was a significant difference in percentual volume regression of the dominant 
leiomyoma between the treatment groups (p=0.014). The controls (N=15) had a percentual n.s. 
increase in volume of mean (± 95% Confidence interval), +8% (-10%, +26%) over time. The 
mifepristone group (N=12) had a significant volume regression of -27% (-47%, -8%), p=0.028 
within the mifepristone group and between the treatment groups at the end of study (p=0.014). 
Mifepristone treatment significantly reduced the number of bleeding days (p<0.001) and 
increased blood haemoglobin values (p=0.046). The breast Ki-67-index was significantly 
reduced by mifepristone treatment (p=0.012). Breast symptoms, like soreness (p=0.035), 
swelling (p=0.028) and the score for sense of increased volume (p=0.043), were reduced 
within the mifepristone treated group. The incidence of hot flushes was more frequent in the 
mifepristone treated group (p=0.012). Endometrial morphology showed no hyperplasia or 
atypia. Microarray displayed 17 pathways significantly changed by mifepristone exposure, 
among which Integrin, EGF, NRF-2 mediated Oxidative Stress response and Ephrine 
pathways were the top 4 most significant. In a subgroup analysis of good (N=4) versus poor 
(N=4) responders, with regard to the effect of mifepristone in induction of volume regression, 
the Glutathione pathway was the second most significant. Among good responders GSTM1 
was expressed, while it was not detectable by Real time PCR in non responders. In primary 
cell cultures, the genes PIK3R1 and PAK3 proved to respond to the antiglucocorticoid effect of 
mifepristone. 
CONCLUSION: Mifepristone may offer an effective, well tolerated preoperative treatment 
option for women with uterine leiomyoma and the associated uterovaginal bleeding. Our results 
also show an antiproliferative effect of mifepristone in normal premenopausal breast 
epithelium, implicating a possible protective effect. It is suggested that GSTM1 may be of 
importance for the response in leiomyoma volume regression as induced by mifepristone, and 
could have a role as a biomarker for tailoring of the medical treatment of uterine leiomyomas.  
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1 INTRODUCTION 
Uterine leiomyomas are composed of fibro muscular monoclonal fusiform smooth 
muscle cells, clones of a single mutated myometrial cell. This was concluded by non 
random inactivation of X chromosome, demonstrated by electrophoresis of glucose 6 
phosphate dehydrogenase isoform expression (G-6-PD) (1). Myocytes and fibroblasts 
are intermingled and oriented in different interconnected planes creating a randomly 
arranged multidirectional network of tissue bundles in a rounded tumor. Usually the 
leiomyoma is of limited size, less than 4 cm in diameter, without any need for medical 
attention (2). The exposure to estradiol (E2) as well as progesterone (P4) is of 
fundamental importance in the proliferation and growth of leiomyomas. The tumor 
almost invariably declines at menopause. Estrogen (ER) and progesterone (PR) 
receptors are over expressed in leiomyomas compared to adjacent myometrial tissue 
(3). Cyclic myometrial cellular changes of proliferative activity are the basis for 
increased incidence of leiomyoma induction by means of leiomyoma cell mutation (4). 
There appears to be genetic variation in leiomyoma prevalence as African American 
women in United States have a 3-fold higher risk of developing leiomyoma (5). 
Leiomyoma related clinically recognized symptoms in terms of bleeding, mechanical 
discomfort or dysfertility occur in up to 50% of women with leiomyoma (6).  
1.1 PREVALENCE 
Uterine leiomyomas are highly prevalent and increase with increasing age. A Swedish 
study reported 18 patients with myomas, with a diameter of 9-80 mm, from a random 
sample of 335 women in the age between 25-40 years. The overall prevalence was 
5.4% (0.95 CI: 3.0-7.8 %), and in a subcohort of women aged 33-40 years, the 
prevalence was 7.8% (3.6%-12%) (7). Higher prevalence of leiomyomas > 2 cm, 
254/641 (40%), was seen on ultrasound screening of a population sample of women in 
the USA. Subsets for ethnicity showed 144/314 (46%) for African American women 
and 110/327 (34%) for Caucasian women, between 35-49 years of age (2). Stratified 
for age, the prevalence of clinically relevant tumors, defined as enlarged uterus > 9 
week pregnancy was 30% for African American women and 10% for Caucasian 
women up to 39 years of age. For women up to the age of 50, the prevalence was 50% 
and 35% respectively.  
1.2 INCIDENCE 
In the Nurse´s health study II, a study carried out on a cohort of 116,678 female nurses 
between the age of 25 and 42 years who were premenopausal and with intact uterus, the 
subjects were followed with questionnaires every second year between 1989 and 1993. 
In 327 065 women years 4181 myomas were diagnosed. The incidence per 1000 
women years was 12.5 (12.1-12.9) for Caucasians and three fold higher (37.9) for the 
African American cohort. The incidence increased with premenstrual age. An incidence 
of 9.0 cases per 1000 women years was seen between 30-34 years of age, compared to 
a more than doubled rate, 22.5 between the ages of 40-44 (5). The yearly hysterectomy 
incidence per 1000 women years, due to leiomyoma, was 2.9 for women between 25-
44 years (8). In Sweden, during 2008, the overall abdominal surgical incidence due to 
heavy menstrual bleeding (HMB) or leiomyomas, among  women 25-44 years of age 
was 1520 out of 1198681 women, thus 1.3/1000 women years. Treatment included 
hysterectomy, supracervical amputation and leiomyoma enucleation but not uterine 
artery embolisation (UAE) or hysteroscopic resection (registry extract Socialstyrelsen).  
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During 1997 in the USA, the proportion of leiomyoma diagnosis and bleeding disorder 
in relation to the choice of surgical technique (9): 
   
Surgical approach  Indication:  Indication: 
(% of all in the category)  leiomyoma  bleeding disorder 
Abdominal subtotal  49.7%  7.3% 
Abdominal total  40.2%  9.5% 
Laparoscopic   28.7%  15.7% 
Vaginal   17.1%  13.6% 
1.3 LOCALIZATION  
The localizations of leiomyomas, (prevalence in brackets) are: submucosal (5%), 
bulging into the uterine cavity with more than half of its size; intramural (75%), mainly 
engaging the uterine wall; or subserous (20%), with more than half of the volume 
located exterior to the uterine wall and occasionally stalked. Stalked intracavitary 
myomas may protrude through the cervix, and cause inversion of the uterine cavity as it 
is delivered through a dilated uterine cervix. The localization is of importance for 
eliciting symptoms such as bleeding disorder or dysfertility, as well as for potential 
mechanical impact upon adjacent organs. Bleeding disorder is mainly associated with 
submucous or intramural tumors (6). 
1.4 LEIOMYOMA SUBTYPES 
In order to guide in the evaluation of whether a malignancy should be considered or not 
leiomyoma subtypes are classified according to the World Health Organization (WHO) 
classification for mesenchymal tumors of the uterus as; mitotically active, cellular, 
hemorrhagic cellular, atypical ,epiteloid and myxoid. Patterns of necrosis, relatively 
acellular zones of hyaline degeneration, are frequently seen (60%), following 
infarctions in benign tumors. Hyaline degeneration is seen as clear amorphous areas in 
leiomyoma sections for microscopy (10). The vascular support to myomas is arranged 
through a vessel network embracing the tumor, branching into centripetal radial 
vessels, towards the central part of the tumor which is often visible upon Doppler 
ultrasound investigation.  
1.4.1 Signs of malignancy 
The issue of malignancy must be kept in mind, and is defined as >10 mitotic figures per 
10 high power fields (HPF) in the microscope. Modifications up or down, as in cellular 
(up to 20 MF) or in myxoid (<2 MF) subtypes, are applied in accordance with the 
WHO classification. Leiomyosarcoma comprise 1.3% of uterine malignancies, and 
30% of the sarcomas. One in 800 leiomyomas proves to be a sarcoma. Gross pathology 
of sarcomas includes: size >10cm; solitary lesions (50-70%); soft, fleshy and yellowish 
cut surface, frequently with the presence of necrosis or hemorrhagic areas.  
1.4.2 Benign tumor characteristics 
Benign tumors are characterized, on the other hand, as frequently multiple, smaller (3-5 
cm), with a firm white whorled cut surface, infrequently appearing necrotic or with 
hemorrhagic areas. Diffuse enlargement of the uterus is also seen in rare conditions, 
like leiomyomatosis, with multiple nodules up to 3 cm increasing the uterine volume. 
The uterine weight may exceed 1000 grams; still without any association to malignancy 
(10).  
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1.5  SYMPTOMATOLOGY 
The clinical symptoms caused by uterine leiomyomas are dominated by an increased 
amount and duration of menstrual bleeding. Less frequently reported is discomfort and 
dysfunctional impact caused by pressure upon adjacent organs such as the bowel, 
urinary bladder or ureter. Dysfertility with decreased chance of pregnancy and an 
elevated risk of spontaneous abortion is concluded in mainly retrospective studies (11). 
1.5.1 Menstrual pattern 
Women with leiomyoma have on average one extra day of bleeding; 5 days, compared 
to women without leiomyoma; 4 days. The relative risk, RR (0.95 confidence interval) 
for bleeding discomfort increases with tumor size. RR 1.9 (1.5 to 2.5) for women with 
leiomyomas >5 cm, among whom a nearly doubled occurrence of gushing flow was 
also seen, compared to women without leiomyomas. Intramural or submucous location 
did not affect the relative amount of bleeding in this study (12). The patophysiological 
mechanism behind excessive bleeding is not yet known. The mechanism could be 
multifactorial involving inflammatory, atrophic or vascular alterations in endometrium 
covering a submucous leiomyoma. The endometrial area from which bleeding is 
released is increased by an intracavitary or transmural leiomyoma. Intramural 
leiomyomas are considered to block the venous return from endometrium by 
pressurizing the venous vasculature at the venule level.  
1.5.2 Pelvic pain 
Pain is not a frequent complaint associated with leiomyoma and any differential 
diagnosis as the cause of abdominal pain should be ruled out. Pain is generated 
whenever perfusion of a leiomyoma is compromised. Occasionally a pedunculated 
leiomyoma may rotate around its own axis and torsion of such a leiomyoma may be 
accompanied with pain. Accelerated growth of the tumor may cause outgrowing of its 
vascular supply, clinically occasionally associated with malignancy. Cervical dilatation, 
due to delivery of a submucosal leiomyoma, is likely to be painful. In an Italian 
population it was reported that among women with leiomyoma, 7% reported severe to 
moderate pain. The OR for dyspareunia was 2.8 (95% CI: 0.9-8.3), and for non cyclic 
Fig 1. 
Uterus and leiomyoma opened longitudinally, with a 6 cm transmural leiomyoma 
with a rather large intracavitary portion. 
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pelvic pain 2.6 (95%CI: 0.9-7.6), compared to women without leiomyoma. No 
difference was found for dysmenorrhea (13).  
1.5.3 Mechanical impact on adjacent organs 
Myomas exceeding 5 cm represent space occupancy and weight that may cause 
pressure and impingement of adjacent organs. A sense of pressure or weight in the 
lower abdomen is a common feature in women with leiomyomas. A myomatous tumor 
with proximity to bowel, bladder or ureter, may elicit significant obstruction and further 
dysfunction such as constipation, urinary urgency, frequency or hydronephrosis (14).  
1.5.4 Dysfertility  
Fertility is more likely to be affected by submucous intracavitary lesions (15). However 
transmural location could interfere with the tubal passage, endometrial receptivity and 
implantation. Leiomyoma is occasionally involved in recurrent spontaneous abortions. 
A currently debated issue is the benefit of myomectomy prior to assisted reproduction 
technique (ART), with or without dislocation of the cavity. Surgical removal improves 
the pregnancy rate following IVF, when there is a cavity involvement or deformation. 
Furthermore intramural leiomyoma without cavity impact has been shown to reduce the 
live birth rate, as well as clinical pregnancy rates, with strong significance (16). The 
IVF pregnancy and abortion rate after removal of myoma prior to IVF was similar to 
that of women without leiomyoma (17). In a population with at least one intramural 
myoma >5cm diameter, without submucous component, IVF was significantly more 
successful in a surgically treated subgroup compared to women who had not undergone 
surgery before the scheduled IVF procedure (18). There is a lack of prospective 
randomized studies in a fertility context. Available studies summarize the outcomes 
from retrospective observations.  
Pregnancy complications such as peripartum hysterectomy OR 13.4 (95%CI: 9.3 - 
19.4), malpresentation OR 2.9 (95%CI: 2.6-3.2), dystocia OR 2.4 (95%CI 2.1-2.7), 
premature delivery OR1.5 (95%CI: 1.3-1.7), placenta abruption OR 3.2, (95%CI: 2.6-
4.0), and caesarean section OR3.7 (95%CI: 3.5-3.9) are significantly associated with 
intramural leiomyomas (17).  
1.6 DIAGNOSIS 
1.6.1 Manual pelvic examination 
The classical finding is a solid, non tender, rounded tumor with smooth surface, 
palpable at bimanual abdomino-vaginal examination, or as an asymmetrical diffuse 
enlargement of the uterine corpus. It is not always possible, in these cases, to exclude a 
tumor originating from the adnexae, bowel or retroperitoneal space. 
1.6.2 Ultrasonography 
Vaginal and abdominal ultrasound examinations are useful tools in order to confirm the 
occurrence of a leiomyoma which appears as an echo dense, rounded tumor in 
association with the uterine corpus. Multiple leiomyomas >4 and sized >375 ml are 
difficult to evaluate by ultrasonography. In contrast MagneticResonance Imaging 
(MRI) is useful in these cases (19). 
1.6.3 Computed tomography (CT) 
Radiation exposure limits the use of CT for scientific purposes. Where malignancy is 
suspected or there is an inconclusive diagnosis, CT may be used for further tumor 
characterization, in order to describe the involvement of adjacent organs for 
preoperative evaluation. 
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1.6.4 Laparoscopy 
Laparoscopy, optionally in combination with hysteroscopy, could be considered as a 
second line standard procedure, following ultrasonography, or MRI, for the diagnosis 
of uterine leiomyoma. The procedure permits complete visualization of the major 
proportion of significant pelvic tumors, and provides evaluation of the peritoneal 
surfaces, with occurrence of peritoneal adhesions and/or coexisting endometriosis. 
Abdominal laparoscopic visualization is compulsory, when non invasive investigations 
are inconclusive. Hysteroscopic examination is of value for diagnostic verification of 
intracavitary leiomyomas as well as lesions, such as polyps and anomalies of the 
uterine cavity. It is possible to carry out various treatments such as extirpation of 
polyps, resection of leiomyoma or a septum within the same surgical procedure. 
1.7 COST FOR THE SOCIETY AND INDIVIDUAL 
In the USA, a database from nine insurance companies, covering 1, 2 million people 
was utilized. Between January 1999 and December 2003, 5122 women between 15-64 
years were diagnosed with leiomyoma. Matched controls without leiomyoma diagnosis 
were randomly selected from the database. The cases were followed during 1 year after 
receiving the diagnosis. Costs for hospitalization, medication and disability claims due 
to absenteeism from work, were registered. During the first year after diagnosis the 
relative risk for hysterectomy was 50 fold greater (21% of women with myoma) among 
diagnosed cases, compared to controls. Direct costs plus indirect costs such as disability 
claims were 6515+ 1677 (total 8192) dollars, compared to 2268+ 844 (total 3112) 
dollars for controls. The excess cost was 5080 dollars (2, 6 fold greater), during the first 
year after diagnosis. In- and outpatient care represented 93% of the total cost for 
diagnosed cases and 80% for controls (20).  
1.8  STEROID HORMONES IN LEIOMYOMA GROWTH REGULATION 
Steroid hormones such as cortisol (C21), progesterone (C21), androgens (C19) are all 
derived from cholesterol while estrogens (C18) are synthesized from androgens by 
aromatase enzyme. Ovarian steroid hormones, estradiol (E2) and progesterone (P4) are 
essential for the growth of leiomyomas. After menopause leiomyomas decline in size 
and invariably go into a process of involution. The steroid hormones are hydrophobic 
compounds that are made soluble in blood by binding to carrier proteins, such as 
transcortin or SHBG, from which they dissociate before entering target cells, by ready 
diffusion across cell membranes. In the target cell interior the nuclear receptor ligates to 
the hormone ligand. The receptor ligand complex dimerizes, release its inhibitory HSP, 
and functions as a transcription factor on promoters for a set of genes involved in the 
biological response to the specific hormone.  
1.8.1 Progesterone 
Progesterone is produced in the theca cells of the ovary and adrenal cortex. The 
compound is of major importance for the regulation of the menstrual cycle and is a key 
hormone for endometrial function and receptivity, embryo implantation and 
maintenance of pregnancy (21).  
1.8.2 Progesterone receptor modulators (PRM) 
A 19-nor, 11β -steroid compound was synthesized and reported in 1981 by Philibert 
and Moguilewsky. It was described as a strong glucocorticoid receptor ligand. The 
antiprogestin property of the compound was found useful for termination of early 
pregnancy, as reported soon thereafter (22) (23). Progesterone receptor modulators 
(PRM) ligate to the PR and inhibit the agonist mediated structural and functional 
reconfiguration of the receptor. Depending on the local tissue prerequisites, such as 
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lack or relative abundance of co activators and co repressors, a selective response to PR 
ligation is seen. Progesterone is considered to be a pure agonist; in contrast, 
mifepristone is regarded mainly as an antagonist and onapristone (ZK98 299 Schering 
AG, Berlin) as a pure antagonist. Several compounds with different degrees of 
antagonist properties such as mifepristone, asoprisnil and ulipristal have been 
pharmacologically and clinically evaluated, and found to be potentially useful for a 
wide spectrum of clinical indications, including leiomyoma uteri, endometriosis and 
contraception (24) (25, 26) (27-29).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.8.3 Pharmacokinetics of mifepristone 
Mifepristone remains bound to serum proteins to a degree of 94- 99%. AAG (α1-acid 
glycoprotein) is the main human serum carrier for mifepristone, up to a dose of 100mg. 
A higher dose of more than 100 mg is characterized by a quick demetylation and 
hydroxylation in the liver by the Cytochrome P450 enzyme CYP3A4. The serum half 
time for mifepristone in a dose of 100 mg daily is 26-48 hours. Mifepristone is, in a 
small distribution volume, metabolized linearly. Metabolites are excreted with bile and 
very low urinary concentrations are detectable. The distribution is non linear at a dose 
of more than100 mg (30). This infers that an oral intake of 100, 400, 600 or 800 mg 
mifepristone, results in the same serum concentration, around 2.5 µmol/L. At a dose 
of> 400mg of mifepristone, mono and di demetylated and hydroxylated metabolites 
exceed the levels of the mother compound in serum. The metabolites bind more weakly 
than mifepristone, but with twice the strength of dexametasone to the glucocorticoid 
receptor (GR) and may be biologically active. GR affinity could be responsible for the 
antiglucocorticoid effect seen at higher doses, with a subsequent activation of the HPA 
(hypothalamus-pituitary-adrenal) axis (31).  
1.9  CELL COMMUNICATION  
The molecules in a signaling pathway behave as switches. The "turning off" is just as 
important as the "turning on" event, in offering options for recovery of the molecules so 
that they are ready for the next activation. In humans there are 520 different kinases and 
150 phosphatases. Two main types of intracellular proteins act as signaling substances: 
one category is serine /threonine kinase that phosphorylates proteins on serine and 
threonine residues; the other is tyrosine kinases that phosphorylate proteins on tyrosine 
residues. The other possibility for phosphate load exchange is to convey GTP binding 
or hydrolysis to proteins. Large trimeric G-proteins take part in submembranous signal 
transduction from G protein coupled receptors (GPCRs) (32). 
 
Fig 2. 
 
Mifepristone  
C29H35NO2 
(8S, 11R, 13S, 14S, 17S)-11-(4-
dimethylaminophenyl)-17- 
hydroxy-13-methyl-17-prop-1-ynyl-
1,2,6,7,8,11,12,14,15,16- 
decahydrocyclopenta [a ]phenanthren-
3-one 
CID: 55245 
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1.9.1 Growth factors-cytokines 
Growth factors or cytokines are signal proteins that apply impact on the cellular 
functions, structures, movements, growth or apoptosis by paracrine cell to cell 
communication, mediated by signal molecules in the extracellular matrix (ECM). Each 
cytokine has its own receptor in the cell membrane, mediating a signal specific 
response to the cellular interior through activation of secondary pathways.   
It is known that a combination of estrogen and progesterone mediated effects are 
necessary to elicit a response in cellular proliferation. This is mediated by the cytokine 
in question. Epidermal growth factor (EGF) is promoted by P4 and its membrane 
receptor (EGF-R) is promoted by E2 (33), both of which are essential for induction of 
proliferation in leiomyoma cells. The sex steroid effect on myocytes is mediated 
through cytokines similar to EGF, and their specific receptors at the cell membrane. 
Cytokines ligate to receptor tyrosine kinases (RTK) that activate G-proteins and further 
induce mitogen activated plasma kinases (MAPKs) with effects on the cellular function 
and cell cycle (34). The autocrine and paracrine abundance of different growth factors 
like EGF and IGF as well as apoptosis protective agents like bcl-2 are likely to 
determine the proliferative net response to steroid hormone stimulation (33). Gene 
expression of EGF in leiomyoma is no different than that the in myometrium during the 
proliferative phase, but in the secretory phase there is an amplification of expression 
suggesting a progesterone dependency (35). RTKs such as EGF-R were shown to be 
over expressed in leiomyoma (36). 
1.9.2 Transcription factors                                                                                                                                                                                                               
Transcription factors are defined as any protein required for the initiation or regulation 
of transcription. Regulatory proteins such as co activators, co repressors and chromatin 
remodeling complexes act directly on RNA-polymerase or via a mediator protein at the 
promoter complex. The promoter is the DNA sequence where general transcription 
factors and the polymerase assemble at the start site of transcription. Gene regulatory 
proteins act by binding to general transcription factors or polymerase. Whereas general 
transcription factors and mediators are the same for all polymerase transcribed genes, 
the gene regulatory proteins and their binding sites relative to the promoter differs 
between genes, modulating the cell specific response (32). 
1.9.3 Nuclear receptors 
Nuclear receptors comprise a super family of transcription factors, involved in several 
physiological functions, as control of cell differentiation and homeostasis. More than 
twenty receptors are classified as “orphan” receptors since the ligand is not yet known 
(37). The N-terminal DNA binding domain (DBD) contains activation function-1 
(AF-1) and regulates the ligand independent activity of proteins necessary for 
transcription. AF-2 is located in the C-terminal Ligand Binding Domain (LBD) and 
regulates the ligand and co regulator recognition (38). All nuclear receptors ligate to 
DNA at hormone response elements (HREs), after dimerization of homo or 
heterodimers, during release of inhibitory HSPs. Impact from auto or paracrine co 
activators or co repressor proteins as well as additional transcription factors are needed 
for induction of transcription. This is followed by further downstream signaling, 
towards mediation of the biological response of the hormone in terms of cascades of 
enzymatic protein activity modulating expressions of downstream genes (39). The 
cellular response to receptor modulation, in terms of agonist or antagonist effect, is 
determined by the cellular relative balance of co activators and co repressors, as well 
as impact from other sub cellular signaling (40).   
1.9.4 Progesterone receptor (PR) 
Nuclear receptors for progesterone are present in the female genital tract, breast, and 
brain. The expression is induced by estrogen. The DNA promoter site for PR 
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transcription, involves a dedicated estrogen response element (ERE). The abundance is 
higher in leiomyomas than in adjacent myometrium (3) (41).  PR exists as at least two 
isoforms, PRA (94kDa) and PRB (99 kDa). PRA (769 a.a.) is a subset of PRB (933 
a.a.), lacking 164 amino acids at the N-terminal. The two isoforms are transcribed from 
a single gene by initiation of transcription from separate promoters and act selectively 
on different sets of responsive genes. The transcription start site for the PRA isoform 
has not yet been determined. For the PRB gene, the transcription start site is located at 
chromosome 11q22.1.  
While the two forms of PR have similar DNA- and ligand-binding affinities they have 
opposite transcriptional activities. PRB functions as an activator of progesterone-
responsive genes, while PRA is inhibitory. PRA functions as a strong repressor of PRB 
and ER activity in the presence of PR agonists and antagonists (42).  
PRA is transcriptionally inactive because of an inhibitory domain, blocked by a PRB 
upstream activating factor AF-3, abundant only in the PRB isoform. Interestingly, 
mifepristone binding induced PRBmutant mediated transcription of β-galaktosidas in an 
agonist mode, indicating that there are separate ligation sites for P4 and mifepristone in 
the utmost C-terminal end of the PRB (43). 
1.9.5 Estrogen receptor (ER) 
Estrogens are involved in cellular processes such as growth, differentiation and 
function of the reproductive system. In females, estrogen principal targets are the 
ovaries, uterus, vagina and mammary glands as well as the brain. The promoter for 
PR is targeted by ER, thus inducing a response in PR synthesis. The ER alfa (ESR1) 
and beta (ESR2) proteins are abundant in the cell nucleus where they persist as homo or 
heterodimers associated with HSPs. By analogy with other nuclear receptors, hormone 
ligation is followed by dissociation of HSP and activation of co activators or co 
repressors, like SRC-1 (NCOA1) (44).  
1.9.6 Cyclicity and mutation 
The risk for development of breast cancer is over all around 10% during a lifetime, pro 
primo related to inheritance and secondly deduced from the cyclic pattern of hormone 
exposure. Estrogens are known to enhance the rate of cell proliferation in glandular 
tissue of the breast, tentatively contributing to mutation, initiation and further 
promotion of breast cancer. Early menarche, nulliparity, high age at first delivery and 
late menopause are factors that increase the number of exposures to cyclic periods of 
proliferative enhancements, suggesting a higher risk for mutagenicity (45).  
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2             AIMS OF THE STUDY 
 
 
 
To study the effect of 12 weeks treatment with low dose mifepristone on: 
 
. 
 Leiomyoma volume, endometrium, bleeding pattern, and side effects. 
 Cell proliferation in normal breast of premenopausal women.  
 Gene expression in leiomyoma. 
 The molecular basis for the difference in leiomyoma volume regression in response to 
treatment. 
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3 MATERIALS AND METHODS 
3.1 PATIENTS 
A prospective, randomized, placebo controlled study was conducted at the Karolinska 
University Hospital, Stockholm, Sweden between November 2004 and June 2007. 
Approval from the Ethics committee (02-410) at the Karolinska Institutet and from the 
Medical Products Agency was sought and given. The study involved women who were 
referred to the hospital for surgery due to uterine leiomyoma in this period. Among 
eligible women (N=72) 42 declined participation while 30 were included in the study 
after giving their written informed consent. Participation criteria included 
premenopausal women with indication for leiomyoma surgery in terms of HMB or 
mechanical pressure or infertility issues, who were otherwise healthy, had not 
undergone steroid hormonal treatment during at least 3 months prior to start of the 
study medication. Normal blood biochemistry profile of the group included 
haematology, hormonal and parenchymatous organs, with verification of 
premenopausal hormonal status.  Mammography was offered, if not already done 
during the 12 months before start of the study. The women underwent endometrial 
biopsy, and routine gynaecological examination including PAP smear and the results 
were evaluated as normal before their inclusion in the study. Ultrasonographic 
examination was also carried out in order to exclude signs of present gynaecologic or 
other malignancy. Criteria for excluding individuals from the study included the 
development of uterovaginal bleeding not possible to control by treatment with 
tranexamic acid and iron supplementation.  
3.1.1 Sample size calculation 
Assuming a standard deviation of 10% in the percentage volume change of leiomyoma, 
18 subjects per group were considered to be required to detect a difference of at least 
10% in percentual volume change between the treated and the placebo group with 90% 
power, using a one-sided 5% level test. Allowing for a 10% drop outs, 20 subjects per 
group, or a total of 40 women needed to be recruited into the trial.  
3.1.2 Treatment 
Eligible patients were randomized into two treatment groups using sequentially 
numbered, opaque sealed envelopes prepared according to a computer-generated 
randomization list by the Karolinska University Hospital Pharmacy. The patients 
received either mifepristone 50 mg (one quarter of 200 mg, Mifegyne
®
, Exelgyn, Paris, 
France) as the active substance or visually identical B-vitamin tablets (one quarter of 
TrioBe
®
 Recip, Stockholm, Sweden) as an inactive comparator, every other day for 12 
weeks starting on cycle day one.  
3.2 CLINICAL PROCEDURES 
3.2.1 Ultrasonography and Doppler  
A general assessment, utilizing TVS (Trans Vaginal Sonography) of pelvic, urinary 
organs, adnexae and uterus with leiomyoma diameters and endometrial thickness was 
performed at baseline, to rule out signs of coexisting pathology. Subsequently 
measurements with four week interval were conducted utilizing aVoluson730 Expert 
(General Electric, Zipt, Austria) with high frequency (7-9 MHz) transvaginal probe. All 
leiomyomas were localized and the diameter in three perpendicular planes was 
measured, the volume was then calculated by the formula describing an ellipsoid: 
=0,523 x d1 x d 2 x d 3. Pulsatile index (PI) = S-D (systolic-diastolic flow) / time average 
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maximal flow (TAMAX) and peak flow were measured in the uterine vessels and from 
the feeding vessels at leiomyoma periphery and in the center of the tumor.  
3.2.2 Blood biochemistry  
Routine blood biochemistry included haematological and parenchymatous organ 
functional parameters. Hormonal status included FSH, LH, estrogen, progesterone, 
testosterone, androstenedione, DHEAS, SHBG and prolactin, as well as 24 hour urinary 
cortisol assessment. Safety parameters for blood and liver status were repeated 
monthly. Hormonal status was assessed prior to initiation of medication and at the end 
of study. Concentrations of free testosterone were calculated from values for total 
testosterone, SHBG and a fixed albumin concentration of 40 g/l (46). 
3.2.3 Questionnaires 
3.2.3.1 Diary 
Patients were asked to keep daily records on any vaginal bleeding, pelvic pain or pelvic 
pressure symptoms, without further estimation of the degree of symptoms. Instructions 
and follow-up was provided by the research nurses. Patients were followed weekly in 
order to check for compliance.  
3.2.3.2 Likert scale 
The Likert scale was used for weekly grading of pelvic symptoms like pain, pressure, 
dysuria or general symptoms like nausea, hot flushes or intestinal dysregulation. 
Changes in mood, headache, and libido were monitored. The scores were determined 
on a 5 point (0-4) Likert scale as; no, weak, moderate, severe or very severe symptoms. 
The scores were reported weekly and summarized in four week blocks, thus possible 
summarized scores were ranging from 0-16 for every treatment month.  
3.2.3.3 Breast symptom index 
A tool was used to assess the patient´s breast symptoms, BSI (Breast Symptom Index), 
by using monthly self registration, monitoring and recording of breast symptoms on an 
11 point scale, from zero to ten. Symptoms, during the preceding four weeks, such as 
soreness, “needle like pains”, pain, swelling and change in size were registered. 
Recordings were collected from baseline and on three consecutive occasions after 4, 8 
and 12 weeks duration of the study. 
3.2.4 Endometrial biopsy 
Biopsy material was sent for histologic evaluation at baseline in order to rule out any 
preexisting atypia, before inclusion in the study. Endometrial biopsies were obtained 
from the fundus of the uterine cavity with a Randall® curette (Stille, Sweden), before 
starting medication and after the treatment period during surgery. In some cases we 
experienced difficulties in obtaining a baseline biopsy due to leiomyoma interference 
with the cervical canal or dislocation of the cervix or corpus.  
3.2.4.1 Routine assessment and for IHC (immunohistochemistry) 
Biopsies were fixed in formalin and embedded in paraffin blocks, prior to sectioning 
and mounted on slides for IHC.  
3.2.4.2 Expert evaluation of endometrial morphology 
Slides were also prepared with hematoxylin and eosin, and sent for a blinded 
assessment for any endometrial morphological changes due to mifepristone treatment 
by Professor Alistair Williams at Edinburgh University. 
3.2.5 Surgery 
The staff and surgeon were blinded to treatment allocation. The decision of the route of 
surgery was defined at the preoperative evaluation and summary of clinical data. 
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Abdominal myomectomy (N=7mif+10contr), abdominal hysterectomy (N=4mif+6contr), or 
vaginal hysterectomy (N=3mif + 0contr) were performed.  
3.2.5.1 Leiomyoma biopsy at surgery 
 Leiomyoma biopsies perpendicular to the dissected leiomyoma surface were obtained 
using a dermal punch. Biopsies were fixed in formalin for embedding in paraffin 
blocks, prior to sectioning and mounting on slides in duplicates for IHC. Biopsies were 
also separately collected and snap frozen in liquid nitrogen for later isolation of total 
RNA. 
3.3 RESEARCH LABORATORY INVESTIGATIONS 
3.3.1 Breast biopsy and Immunocytochemistry analysis 
Percutanous FNA from the upper outer quadrant of the left breast were performed at 
baseline, during the luteal phase and repeated at the end of treatment, close to the 
surgical intervention. FNA biopsies were performed using a needle with an outer 
diameter of 0.6 mm as previously described. A fine needle was used in order to 
minimize the trauma for patients and to allow a repeat biopsy after 3 months. By 
palpation of the breast it is often possible to localize the mammary gland for optimal 
procurement of MECs (mammary epithelial cells). In order to produce multiple 
identical slides, aspirated cells were suspended in 1.0 ml 4% buffered (pH 7.4) 
formalin. Cell suspensions of 110 µl were centrifugated in a cytocentrifuge at 700 rpm 
for 3 min at room temperature, and the cells were collected on to glass slides. Slides 
were probed for the nuclear antigen Ki-67 with the MIB-1 monoclonal antibody 
(Immunotech ®, Marseilles, France). Ki-67 is present in proliferating cells but absent in 
quiescent cells. Immunostained epithelial cells were quantified by cell counting at 200-
fold magnification, simultaneously by two independent observers. An index for 
proliferativity in breast tissue, Ki-67 index, was calculated by dividing the Ki-67 
positive cells with the number of unstained cells, not in the process of proliferation. The 
Ki-67 index was considered valid only if >50 unstained cells were obtained. As the 
usual percentage is around 2%, one stained cell among 50 not stained is expected. 
Thus, 50 MECs validates the Ki-67 index for premenopausal normal breast tissue. 
3.3.2 Immunohistochemistry (IHC) 
3.3.2.1 IHC endometrium 
Both steroid hormone receptor expressions and Ki-67 were analysed by IHC in the 
luminal, glandular and stromal compartments of the endometrium.  
The tissue sections were deparaffinized hydrated and quenched with hydrogen peroxide 
to inactivate the tissue peroxidase activity. The primary antibody was added targeting 
the receptor protein of interest. For procedure details, please see papers II and IV. 
Sections were evaluated by two independent investigators, blinded to treatment, using 
the IRS (Immuno Reactive Scoring system), a semi-quantitative subjective scoring 
system based on both percentual positive (PP) and staining intensity (SI) as follows. 
IRS = SI * PP, mean of 10 visual fields. SI was visually graded as 0= no staining; 1= 
weak staining; 2:=moderate staining and 3=strong staining and PP as the percentage of 
cells stained positive. The PP was estimated by counting approximately 200 
background cells, and was scored as 0= no staining, 1= <10%, 2= >11<50%, 3= <80% 
and 4>81% stained (47). With regard to Ki-67, immuno reactivity was heterogeneous 
with no grading of intensity. Fewer cells were stained compared to the background. The 
scoring template was therefore modified as follows: 0=no cells stained; 1=<5%, 2=> 
5<10%, 3=>10<20% and 4=>20% of cells stained, compared to background count. All 
expressions were evaluated by two independent researchers, blinded to treatment 
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allocation. Inter observer correlations for the significantly upregulated PRB and 
PRA+B was good, r=0.7 (p=0.005) and r= 0.9 (p<0.001) respectively. 
3.3.2.2 IHC leiomyoma  
The expression of steroid hormone receptors (ERα, ERβ, PR, growth factors -EGF, 
FGF), caspase-3 and proliferation marker Ki-67 was assessed by IHC. The tissue 
sections were treated as described in paper IV. A multiplicative modified 
“Quick”scoring was used, with the staining intensity 0-3 (no staining, weak, 
intermediate or strong staining) multiplied with a score for percentage (1-4) between 
(1) <25, (2) <50, (3) <75, (4) <100% of cells stained, with a calculation of the mean for 
ten visual fields. In the case of steroid receptors (PR and ER), growth factors and 
caspase-3 we scored the cross cut and oblique bundles separately.  The scores 
correlated less well between observers. In general the cross cut scores were 1.4 fold 
higher than scores from the obliquely cut cells. From 10 HPFs scores were determined 
by two independent assessors.  The mean of scores from two blinded assessors gave the 
immunoreactive score (IRS) for the protein analyzed in two categories, cross cut or 
oblique bundles.  
For Ki-67 a modified scoring system was applied, counting the number of Ki-67 
positive cells per visual field (x400 magnification) in ten HPFs. The mean value for 10 
HPFs was used as an assessor specific index value for the case. Evaluations were 
performed by two independent researchers blinded to the treatment allocation. The inter 
observer scores correlated (r=0.52, p=0.049). The mean of scores from two observers 
represent the proliferative index for the case.  
3.3.3 RNA extraction 
Samples were homogenized in a Retsch® tissue mill at a shaking frequency of 30/sec 
according to the supplier‟s instruction. Total RNA was isolated using Trizol ® reagent 
(Life technoclogies; Invitrogen Corp. & Applied biosystems Inc., Carlsbad, California).  
The RNA extracts were stored in a freezer at -70 degrees C until reverse transcription 
into cDNA was carried out. The quality of RNA was checked using NanoDrop 
(Thermo scientific Waltham, MA, USA) as well as by running it on agarose gel. All 
samples had an OD260/280 ratio > 1.8.  
3.3.3.1 cDNA synthesis 
One microgram of total RNA was reverse transcribed to cDNA using Superscript II™ 
Reverse Transcription (Invitrogen) with Ribonuclease Inhibitor (RNasin, Promega 
Corp., Masden, WI) in a 20 microliter reaction volume. The synthesised cDNAs were 
diluted 1:2.5 in Millipore™ purified, autoclaved sterilised H2O kept as „stock‟ solutions 
in a freezer at -70 degrees C until used. 
3.3.4 Microarray 
3.3.4.1 Control versus Mifepristone 
The total RNA from three cases per category was reverse transcribed to cDNA and 
labelled with probes and was hybridized onto the microarray chip.  
 The microarray on an Applied Biosystems Human Genome survey Microarray V2.0 
was processed at core facility - Karolinska Biomics Center. The data from the 
microarray analysis was normalized against each other and > ±1.5 fold, and significant 
(p<0.05) change in the expression levels were calculated using Analysis of Variance. 
The filtered set of significantly different genes with fold changes were uploaded to IPA 
(Ingenuity Pathway Analysis) software (48).  
3.3.4.2   Good versus poor responders 
A subgroup of mifepristone treated cases, were subjected to comparison of the gene 
expressions in one group responding with growth regression (N=4), compared to a 
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group of refractory cases, also treated with mifepristone (N=4). The objective was to 
study the molecular background for the observed difference regarding growth 
regression response. Total RNAs were reverse transcribed to double stranded DNA, 
which was transcribed into cRNA labeled with probes using T7 promoter and   was 
hybridized onto the microarray chip. Microarray on an Affymetrix 46.000 genes 
platform (GeneChip Human Gene 1.0 ST Array) was processed at Bioinformatics and 
Expression Analysis core facility (BEA). The data from the microarray analysis was 
normalized against each other and > ±1.5 fold, and significant (p<0.05) change in the 
expression levels were calculated using Analysis of Variance. The filtered sets of 
significantly different genes with fold changes were uploaded to IPA.  
3.3.5 Real Time PCR 
Real time PCR was performed to evaluate and, when possible, confirm the findings 
from microarray analysed by IPA. 
3.3.5.1 Real time PCR; control versus mifepristone group 
For details of Real time PCR analyses, (please see paper IV). cDNAs from seven 
women from the control group and 8  from the mifepristone group were subjected to 
Real time PCR amplification of target genes as evident from IPA analysis and 
microarray. Seven target genes (microarray fold change) in the Ephrin pathway: 
GRIN2A (-3.3), CREB5 (-2.5), ROR1 (+3.6), ITGA3 (-2.4), PIK3C2G (-3.9), EFNB2 
(-2.8), PAK3 (-1.9), and eight in the Integrin pathway: ARHGAP26  (+3.3), ITGB5 
(+2.5), ITGA3 (-2.4), ITGAD (+2.0), PAK3 (-1.9), ROR1 (+3.6), PIK3C2G (-3.9), 
PIK3R1(-2.9). Olionucleotide primers and dye-labeled TaqMan probes, specific to 
seven target genes in Ephrin and eight in Integrin pathway were purchased from 
Applied Biosystems.  
In addition MKI67 (-1.9), TP53 (+1.3) and CKDN1 (+1.6) were assessed for reference 
and correlations. Target gene Taq Man probes were FAM™ dye-labelled and 18S 
cDNA probes were VIC
™
 dye-labelled. The 18S and target gene were processed in the 
same well for optimal validation. Real time-PCR reactions were carried out on 96 well 
optical PCR plates with reaction volumes of 25µl in a 7300 Real Time PCR System 
(Applied Biosystems). Upon analysis after Real Time PCR, one case in the 
mifepristone group was excluded because of outlying low 18S content; the remaining 7 
cases in each group were subjected to statistical analysis.  
3.3.5.2 Real time PCR; good versus poor responders 
The same procedure as for the previously described Real Time PCR was performed, 
(see paper III). Two subsets of cases from the mifepristone treated group, were 
categorized either as good (N=4) or poor (N=4) responders to mifepristone. Three cases 
from each group were subjected to microarray and IPA analysis. A strong difference of 
expression for genes in the Glutathione pathway was seen: Glutathione-s-transferase 
mu 1 (GSTM1 +8.03), glutathione-s-transferase mu 3(GSTM3 +2.26), glutathione-s-
transferase mu- 5  (GSTM5 +2.23), glutathione peroxidase2(GPX2 -1.7). For the 
reference genes, progesterone receptor (PGR +1.09), estrogen-receptor alfa(ESR1 
+1.09),  p-21 activated kinase3 (PAK3 -1.01), the proliferation marker MKI67(-1.02) 
and the apoptosis marker TP53 (+1.19). Glutathione and reference genes were assesed 
with  Real time-PCR, for confirmation of differences. Primers and probes were 
purchased from Applied Biosystems and processed in the 7300 PCR system.  
3.3.6  Primary cell culture study  
Nine patients with myoma, otherwise healthy, without any preoperative hormonal 
medication, were recruited to the study. The cases were decoded and after consultation 
with the ethical committee it was decided that ethical permit was not necessary. All 
experiments were repeated using cells isolated from five different patients. The biopsies 
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were collected during surgery and were placed in Ham F10 medium. The samples were 
finely minced in sterile petridishes at 4˚C, suspended in F10 medium and centrifuged at 
460g for 1 min. In order to remove extracellular matrix, the tissue was digested with 
collagenase type 4, incubated at 37˚C for 4h with adequate shaking. DNase I 0.2mg/ml 
at final concentration was added after 2.5 h incubation. At the end of the 4h incubation, 
the tissue was resuspended gently using a Pasteur pipette. The cells were pelleted at 
460g for 5min at room temperature and resuspended in fresh Ham F10. The cells were 
filtered using 40 µ cell strainer into petridishes. The cells were counted and frozen for 
further experiments. Cells were cultured in DMEM containing 10% FBS, 1% 
antibiotics in collagen coated petriplates at 37 ˚C with 5% CO2 in air. Primary cells 
were used until passage five to avoid variations in phenotype and gene expression. The 
monolayer cell cultures, at about 70% confluence were treated with 2.5% charcoal 
activated serum overnight prior to treatment with 2.5% vehicle control (ethyl alcohol 
0.01%), progesterone (P) (318nM), mifepristone (M) (318nM), and dexamethasone (D) 
(318nM) individually and/or in combinations P, P+M, P+D or P+M+D for 24 hours. 
Cells were harvested and lysed, total RNA was isolated to synthesize cDNA by reverse 
transcription following the same protocol as earlier described.  
3.3.6.1 Real time PCR 
 The integrin genes ARGHAP26, ITGB5, ITGA3, PAK3, ROR1, PIK3R1 and for 
correlations and reference TP53, MKI67 and CKDN1, were subsequently assessed with 
Real time PCR analysis, for assessments of the respective gene expressions during 
different conditions. 
3.3.7 TUNEL  
(Terminal deoxynucleotidyl transferase dUTP Nick End Labeling assay). In order to 
assess the degree of apoptosis, in situ end labeling of the 3‟OH end of the DNA 
fragmentation was performed using the  “In Situ Cell Death Detection kit, Fluorescein” 
(Roche Applied Science). Paraffin embedded leiomyoma biopsy sections were 
dewaxed by heating and serial washings in xylene, a graded series of alcohol and 
finally distilled water, for tissue rehydration. The tissue sections were permeabilised by 
treatment with proteinase K and incubated with the TUNEL reaction mixture (TUNEL 
labeling solution and enzyme) for 1h at 37 ˚C in the dark. The slides were rinsed with 
phosphate-buffered saline and counter stained with DAPI (4', 6-diamidino-2-
phenylindole). Positive controls were prepared by treating slides with DNAse I 
(1000U/ml) for 10min at 25˚C before incubating with TUNEL reaction mix. Negative 
controls were prepared by incubating the slide with TUNEL labeling solution without 
the enzyme.  Analysis and scoring was performed by two independent investigators 
under a fluorescence microscope with excitation wavelength 450nm. The mean of 4 
scores, apoptotic index (AI), was calculated for each case and statistically analysed. 
The correlation observed for inter individual scores was good (R=0. 78, p<0.001). 
3.4 STATISTICAL METHODS 
Mann-Whitney U rank analysis was applied in order to test for significance between 
groups of continuous or ordinal scale data (symptom scores). For differences within 
groups paired dependent values were analysed with the Wilcoxon signed rank test.  
Spearman rank analysis was used to show correlations. Non parametric analysis 
utilizing Friedman‟s model was used for analysis of Real time PCR assessed gene 
expressions in cell culture. The significant differences between the groups were 
subsequently analyzed with Wilcoxon paired tests. Analysis for group differences in 
gene expressions such as dCts  were performed using  the Mann Whitney U test.  For 
microarray, T-test analysis was utilised in order to select items for further analysis in 
IPA. For Real time PCR the mean value of sample triplicates were used for 
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normalisation versus the mean dCt of the “housekeeping” gene 18S ribosomal RNA, to 
obtain a ΔCt (∆ cycle threshold) value. Differential expressions between the control and 
active groups were calculated for each target gene (ΔΔCt).  A P-value of <0.05 was 
considered as significant. 
   17 
4 RESULTS 
4.1 PATIENTS AND RANDOMIZATION 
Two women were not included in the study in spite of eligibility and obtained patient 
consent for participation. One due to a baseline ultrasound evaluation indicating a 
leiomyosarcoma and the other due to psychiatric problems. Because of reorganization 
of the clinic, recruitment had to stop when 30 women had been included and 
randomized. Two patients from the control group were excluded after randomisation, 
one because of elevated FSH, and the other after six weeks, because of uterovaginal 
bleeding in which required surgery without further delay. With regard to 
ultrasonographic volumetric assessments we had two further patients drop out of the 
study, one due to difficulties in determining the leiomyoma borders the other due to 
absence of an operator for the ultrasonography equipment. Twelve mifepristone cases 
and 14 control cases remained per protocol. Data was analysed for myoma volume 
regression, N=15ctr and N=14mif, per protocol.  
In order for breast biopsies to be useful, it was essential to have a minimum of 50 
mammary epithelial cells to evaluate. Eight cases in the mifepristone group and 6 in the 
control group were assessable at baseline biopsy as well as at the end of study.  
Study medication was initiated at the first day of menstruation. The mean (±SEM) 
duration of treatment days were 85±1 days in the mifepristone group and 83±2 days in 
the control group up to the day prior to surgery.  
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4.2 CLINICAL OUTCOME PARAMETERS 
4.2.1 Leiomyoma volume and hemodynamic 
The median (interquartile range) volume (ml) of the dominant leiomyoma at baseline 
was 97 (42–192) in the control group and 137 (111–163) in the mifepristone treated 
group. This difference was not significant. The volume of the dominant leiomyoma 
exceeded 375 ml in only one patient per treatment group at the end of study. The 
median (range) number of leiomyomas at baseline was 2.0 (1–4) in the control group 
and 1.5 (1–4) in the mifepristone group.  
For the dominant leiomyoma, from baseline to the end of study, the mean percentual 
volume increase (± 95% confidence interval (CI)), was +8% (95% CI:-10 to 26) in the 
control group (N=15). The change was not significant within the control group.  
The mean percentual change of the dominant leiomyoma at the end of study in the 
mifepristone group (N=12) was -27% (±95% CI: -47 to -8), (p=0.028 within group), 
this represents a significant change compared to the control group (p=0.014).  
The total myoma volume % change, in the control group was +6% (95% CI -13% to 
25%), which represents a significant difference when compared to the volume % 
change of -28% (95% CI -48% to -8%), (p=0.021) in the mifepristone group at the end 
of study. See table I. 
No differences were seen for uterine and leiomyoma vascular impedance (PI) and peak 
flow measures. There was a pronounced variability among the obtained hemodynamic 
measures. 
 
Table I 
Leiomyoma volume change of the dominant and total leiomyoma volume expressed as median and IQR 
(interquartile range). The percentual change of volume is described as mean (±0.95 confidence interval). 
 
Volume (ml) Control Mifepristone 
Baseline 
(N=16) 
End of study 
(N=15) 
P= Baseline 
(N=14) 
End of study 
(N=12) 
P= 
Dominant myoma 
median (IQR) 
97 (42-192) 85 (68-160) n.s. 137(111-163) 96 (42-129) 0.028
a 
% change 
mean (±0.95 
confidence interval) 
 8 (-10 to 26) 0.014
b 
 -27 (-47 to -8) 0.014
b
 
Total myoma  
 median (IQR) 
134 (53-196) 118 (80 -160) n.s. 161 (111-209) 106 (52-205) 0.023
a 
% change total 
mean (±0.95 
confidence interval) 
 6 (-13 to 25) 0.021
b 
 -28 (-48 to -8) 0.021
b 
a 
p-value within group from baseline to the end of study 
b 
p-value between the groups at the end of study 
The percentual change (%) was distributed with skewness < ±1 permitting report as means and 95% confidence 
interval.  
P-values were calculated by the use of non parametric Mann Whitney U-test between groups and Wilcoxon 
signed rank analysis for paired values over time. 
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4.2.2 Uterovaginal bleeding 
There was a similar distribution of age, menstrual days and cycle length in the 
treatment groups, as well as the indication for myoma surgery. During the first 4 weeks 
of treatment the control group bleeding day count for bleeding was median (range) 7.5 
(2-19), and for the mifepristone group 7 (4–10).  A highly significant reduction (p = 
0.001) in bleeding days occurred during week 5–8 compared to the first 4 weeks of 
treatment within the mifepristone group. The bleeding days were 0 (0–2). In contrast, 
the count for the control group remained 7.5 (3–26). The difference between treatment 
groups was highly significant (p < 0.001). Only two women in the mifepristone group 
reported bleeding for 1 and 2 days respectively during treatment weeks 5–8. Only one 
of these patients reported spotting on one occasion during treatment week 9–12, while 
the control group had 3 (0–27), days of bleeding. Thus 86% of patients in the 
mifepristone treated group were completely free from vaginal bleeding during 
treatment week 5-8, and almost 100% during the last four weeks of treatment.  
4.2.3 Local and general symptoms 
4.2.3.1 Diary data 
No significant changes between or within the groups were observed in daily self reports 
of pain, pressure and sense of heaviness in the pelvis. 
4.2.3.2 Local and general symptoms 
Likert scale scores were evaluated weekly by the participants for local and general 
symptoms like pelvic pain, backache, abdominal pain, bowel dysfunction, bladder 
dysfunction, dyspareunia as well as general symptoms like change of mood, headache, 
nausea or vomiting, decreased libido, hot flushes or loss of general energy. For the 
control group the score for hot flushes was median (range) at baseline 0 (0-2), and at 
the end of study 0(0).  For the mifepristone group score at baseline was 0.5 (0-7) and at 
Fig 3. 
Distribution of leiomyoma volumes (ml) over time, during 12 wk treatment. The spread of volumes is visualized for both 
groups, the trend of regression, is prominent within the mifepristone treated group (p=0.028). One case in the control group 
was extremely outlying and not included in this graph. Due to heavy bleeding she was excluded after 6 weeks.  
 
ml 
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the end of study 3.5 (0-16), p=0.002 within the group and between treatment groups, 
p=0.012 at the end of study. 
4.2.3.3 Effect on breast symptoms 
Significant differences between the groups, was found for swelling and pain (p=0.038). 
No difference was found between the groups for needle like pains, soreness, or sense of 
increased volume at the end of study. The parameters reaching significant change 
within the mifepristone group (mean±SEM) were soreness, 2.43±0.70, at baseline 
against 0.71±0.58, at the end of study (p=0.035). Swelling 1.93±0.78 at baseline versus 
0.0±0.0 at the end of study (p=0.028). Increased breast volume scored mean 2.14±0. 90 
at baseline and 0.36±0.36 at the end of study (p=0.043). In summary, all symptoms of 
breast soreness, swelling, pain or sense of increased volume at baseline faded out 
almost completely towards the end of study.   
4.2.4 Hematology parameters 
The difference in hemoglobin values between the two groups was significant after 12 
weeks treatment (p=0.046). Within the mifepristone group hemoglobin significantly 
increased from baseline (mean±SEM) 121±5 g/l, to 133±3 at the end of study, p= 
0.003. For the control group hemoglobin from baseline to the end of study was 
unchanged (mean±SEM) 124±16 to 122±17 g/l.  
 
 
4.2.5 Serum steroid levels 
For details, see table I in paper I. A significant increase in androgens and their 
precursor, androstenedione was observed in the mifepristone group compared with 
controls/baseline. Estradiol was significantly lower at the end of treatment compared 
with baseline (p=0.004), but still in the range of proliferative phase levels. Urinary 24 
hour cortisol did not change during treatment within or between treatment groups.  
4.2.6 Endometrial histology 
No atypia or complex hyperplasia was seen among the patients included in the study. 
Histological analysis was done blinded to treatment group. In 8 out of 12 samples in the 
mifepristone group and 11 out of 14 samples in the control group it was possible to 
evaluate the morphologic structure and mitotic index (0-3). None of the biopsies 
showed any evidence of hyperplasia or malignancy. Seven out of eight mifepristone 
cases (for definition see Paper II) and 4 from 11 controls were classified as presenting a 
non physiological histology pattern. Cystic glandular dilatation occurred almost 
exclusively  in the endometrium of mifepristone treated women and was present in 5 
out of 8 cases compared to 1 out of 11 control cases (p=0.041, as calculated by Fisher´s 
exact two tailed test in contingence table). No differences between groups were 
observed in abnormal vessels or mitotic index. 
Fig 4. 
Hemoglobin levels during 
mifepristone treatment, 
significantly improved from 
baseline, 4, and 8 weeks 
compared to the end of study. 
Hemoglobin was significantly 
higher in the mifepristone treated 
group after 12 weeks of treatment 
(p=0.048). 
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4.2.7 Breast epithelial proliferation 
Fine needle aspiration biopsy (FNA) was conducted on average 6 days before the start 
of study medication and was repeated preoperatively at the end of study. Steroid 
hormone blood levels were similar in both groups at baseline. In total, 58 breast 
biopsies were obtained, 30 at the baseline and 28 at the end of treatment (see paper I). 
The remaining 28 women were those who completed the study. Menstrual and 
hormonal data were used to verify luteal phase at the time of the baseline biopsy. 
Progesterone levels showed no significant differences between the groups at baseline or 
at the end of treatment. A total of 56 (28 pairs) biopsies were analysed. 14 (50%) had 
assessable paired samples, 8 from the mifepristone group and 6 controls. Previous 
studies show comparable dropout frequency for repeat biopsies, where MECs from 
both occasions must meet the assessability criteria (49) (50).  For the control group Ki-
67 index at baseline median (range) was 2.2 (1.3-21.1) and at the end of the study 4 .1 
(0.0-28.5). For the mifepristone group Ki-67 index at baseline was 5.9 (0.4-10.9) and at 
the end of study 0.8 (0.0-1.86). The reduction of Ki-67 index within the mifepristone 
group was strongly significant (p= 0.012). 
 
 
 
 
 
 
 
 
 
 
4.3   IMMUNOHISTOCHEMISTRY  
4.3.1 Endometrium 
4.3.1.1 Steroid receptors 
On surgery endometrial biopsies were obtained, fixed in formalin and paraffin 
embedded. Sections were mounted on slides. Staining was conducted for the nuclear 
receptors ER-α, ER-β, PR-B and PR A+B, androgen receptor (AR) and Ki-67. 
Mifepristone increased the expression of ER-α (p=0.012), PR-B (p=0.017) PR (A+B) 
(p=0.039) and AR (p=0.04) for the glandular endometrial compartment. In luminal 
epithelial cells PR (A+B) increased (P = 0.03) compared to the control group. No 
differences for steroid receptors were observed in the stromal compartment. 
 
Fig 5. 
FNA biopsies from the left breast of the same patient, at baseline and after 12 weeks 
treatment with mifepristone. 
Brownish coloured nuclei => Ki-67 immunoreactive, proliferative MECs. 
 
A: Before treatment;  B: After 12 weeks mifepristone exposure. 
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4.3.1.2 Ki-67 immunoreactivity 
At the end of study mifepristone significantly down-regulated the expression of Ki-67 
in the stromal compartment compared with controls (P =0.026). 
4.3.2 Leiomyoma 
4.3.2.1 Steroid receptors and growth factors 
For mifepristone treated cases immunohistochemistry showed IRS up regulation for 
ERα in the diagonally cut category, median (range) 6 (3-10.5) p=0.035 compared to 4 
(3-8) for controls, (p=0,059 for the cross cut category). There were no significantly 
different IRS scores for ER β, PR-B, PR A+B, Caspase-3, FGF or EGF in any of the 
categories. 
4.3.2.2 Ki-67 immunoreactivity 
For Ki-67, there was a significant reduction of proliferative index in the mifepristone 
treated group (N=9) mean (range) 5.0 (1.0-15.5), and for the controls (N=8) 15.3 (2.5-
57), p=0.049. 
 
4.4 GENE EXPRESSION: MIFEPRISTONE VERSUS CONTROL GROUP  
4.4.1 Microarray 
In the mifepristone group 3624 genes were changed by 2-fold or more in comparison 
with the control group. Among these, 113 genes were upregulated more than fivefold, 
and 62 were downregulated more than five fold upon mifepristone treatment. Ingenuity 
pathway analysis (IPA) showed changes in eighteen canonical pathways. The most 
significant pathway upon IPA analysis was the Integrin pathway (p=0.0007). Upon IPA 
processing, the EGF pathway was the second most significant pathway (p=0.002). The 
third most significant pathway was the Nrf2-mediated oxidative stress response 
pathway (p=0.005). The Ephrin pathway (p<0.007), was the 4th most significant 
pathway. 
4.4.2 Real time PCR 
 
 Gene expression, significant  results from the Integrin pathway:  
 ROR1, receptor tyrosine kinase-like orphan receptor 1, (PCR fold change: +3.1, 
p=0.013 (microarray fold change + 3.6)). 
 PIK3R1, phosphoinositide-3-kinase, regulatory subunit 1 (PCR fold change 
 -1.8 , p=0.038 (microarray fold change -2.9)).  
 
 Gene expression, significant results from from the Efrin pathway:  
 GRIN2A, Glutamate receptor ionotropic N-methyl D-aspartate 2A, (PCR fold 
change -5,6, p=0.041 (microarray fold change -3.3). 
 CREB5, cAMP response element binding protein 5, (PCR fold change -2,3, 
p=0,030, (microarray fold change -2.5)). 
 ROR1 receptor tyrosine kinase-like orphan receptor 1, (PCR fold change +2,5, 
p=0,021, (microarray fold change + 3.6)).  
 
Confirmation of the microarray screening and IPA analysis was performed in order to 
verify the fold changes found in significant pathways by further analysis utilizing Real 
time PCR. Ten out of fourteen genes were confirmed by Real time PCR as similarly 
changed compared to microarray. Seven controls and 8 samples from the mifepristone 
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group were subjected to Real Time PCR amplification of Integrin and Ephrin pathway 
target genes, and the cell-cycle related genes: TP53, MKI67, and CDKN1A were also 
checked for correlations. Seven cases in each group were used for statistical analysis. 
One gene expression, PAK3, p21-activated kinase 3, showed linear correlation 
(p=0.006) to the clinical percentual volume regression of the dominant leiomyoma in 
the mifepristone treated group. The slope is significantly different for the mifepristone 
treated group compared to the controls. The difference as analysed by ANCOVA, 
between groups in degree of association between PAK3 expression and percentual 
myoma volume regression is significant (p=0.048). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 6. 
PAK3 dCts are correlating to percentual volume regression of the dominant 
myoma. The difference between treatment groups was significant upon 
ANCOVA, analysis of slopes for correlation curves (p=0.048) 
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4.5 GENE EXPRESSION: GOOD VERSUS POOR RESPONDERS 
 
 
 
 
 
 
 
 
 
 
4.5.1 Microarray 
The mean signaling values for the good and poor responders were analysed (utilizing 
IPA). Twentyone canonical pathways showed significantly different expressions (p 
<0.05)  for good and poor  responders to mifepristone treatment. The most differently 
expressed pathway was Metabolism of Xenobiotics by Cytochrome P450 pathway 
(p=1.9*10
-7 
). Participating glutathione s-tranferases have an impact on the cell-cycle 
and aldo-ketoreduktases are involved in the metabolism of sex steroids and the 
neutralisation of  ROS (reactive oxygen species).  
The second most significant pathway was the Glutathione pathway harboring 
glutathione-s  tranferases (p=0.0001). The pathway includes: GSTM1, glutathione S-
transferase mu 1 (fold change +8.0); GSTM2, glutathione S-transferase mu 2 (fold 
change +1.5 fold); GSTM3, glutathione S-transferase mu 3 (fold change +2.3 fold); 
GSTM5 glutathione S-transferase mu 5 (fold change +2.2). Gene expressions in the 
glutathione pathway overlapped in the Nrf-2 mediated antioxidant pathway. The 
rationale for choosing the glutathione pathway for further Real time PCR analysis, was 
the occurrence of an optional biomarker molecule such as GSTM1 and also the 
participation in the Nrf-2 mediated antioxidant pathway.   
4.5.2 Real time PCR 
Taq Man primers and probes were purchased for Real Time PCR analysis for the 
specific  genes: GSTM1, GSTM3, GSTM5, and as reference genes ESR1,PGR,and 
PAK3,MKI67 and TP53. Among the glutathione genes GSTM1, GSTM3, GSTM5 and 
glutathione-peroxidase-2 (GPX2), only GSTM1 was differently expressed in the good 
responder group as compared to the poor responders. GSTM1 was not expressed at all 
among the poor responders.   
Fig 7. 
A marked variation in myoma volume regression was observed in both groups. Two 
mifepristone treated cases had almost 20% volume increase; they were categorized 
as poor responders to mifepristone. The two strongest responders showed a volume 
reduction of -60 and -80% respectively. The population standard deviation was 30% 
(33% for controls, and 30% for the mifepristone treated group). 
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4.6 TUNEL ANALYSIS 
Terminal deoxynucleotidyl transferase dUTP Nick End Labeling assay was done on 
deparaffinized tissue sections.There was no significant difference between the 
treatment groups in apoptotic index (AI). For the mifepristone treated group (N=12): 
the median (min, max) was 7.3 (1.4 -56.7), and for controls (N=9) 17.4 (1.8-130.0). 
Furthermore, there was no significant difference in AI between the good (N=4): 2.0 
(1.4-8.5) and poor responders (N=4): 5.6 (5.1- 28.6). Higher ranks and more variation 
was seen among the poor responders. The interobserver correlation was good 
(R=0.78.p<0.001). 
4.7 PRIMARY CELL CULTURE 
It was possible to analyse five biopsies out of nine.Total RNA was isolated and cDNA 
was reversely transcribed. Real time PCR was conducted and the significant genes by 
Friedman analysis were tested for significance between exposure groups utilizing the 
Wilcoxon signed rank test. We found significant anti glucocorticoid responsiveness for 
PIK3R1 and PAK3. Addition of dexamethasone reversed the gene expression for 
PIK3R1. A down regulative response to dexamethasone on PAK3 expression was 
quenched by mifepristone (See details in Table VI paper IV). 
 
         
 
        
 
 
 
 
 
 
 
Fig 8. 
 
Prog: Progesterone (P) 
Mif: Mifepristone (M) 
Dex: Dexamethasone (D) 
 
PIK3R1: P+M was 
reversed with P+D 
(p=0.043).  
 
 
 
 
 
PAK3: P+M+D group 
completely quenched the 
negative gene regulation 
induced by P+D, and 
therefore is considered as 
antiglucocorticoid 
responsive. 
 
 
 
Fold 
change 
Fold 
change 
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5 DISCUSSION 
5.1 SUMMARY 
The present thesis gives support for the implementation of mifepristone for 
preoperative treatment before leiomyoma surgery. In the study mifepristone treatment 
resulted in a rapid and significant reduction in vaginal bleeding and amenorrhea with 
subsequent improvement in hemoglobin level. A reduction in leiomyoma volume was 
seen without any dysplastic changes in the endometrium or negative effects on cortisol 
levels.  
For the first time in vivo, we report that proliferation in normal breast tissue is reduced 
by mifepristone treatment.  
Adverse effects from treatment were sparse, except for, mostly low intensity hot 
flushes. Breast discomfort in terms of soreness, swelling and a sense of increased 
volume declined almost completely in the mifepristone treated group.  
Comparing the two groups, leiomyoma tissue gene expression changes, are seen most 
significantly in the Integrin and Ephrin pathways, as evaluated by microarray analysis 
processed in IPA. Gene expressions were correlated to percentual regression of 
leiomyoma volume as assessed with ultrasonography, with a positive correlation 
between p21-activated kinase 3 (PAK3) and volume regression. Furthermore, 
leiomyoma growth reduction was dependent of the expression of GSTM1. Since there 
is a marked variation in leiomyoma regression in response to mifepristone treatment, 
GSTM1 determination could provide useful information for preoperative selection of 
cases for this treatment. We propose GSTM1 as a prospective novel biomarker for 
leiomyoma regression during mifepristone treatment. 
The antiproliferative and thus potentially protective effect on the normal breast is a 
finding of great interest for further studies of PRMs in treatment regimens with longer 
duration. Mifepristone has been shown to be highly effective for contraceptive use 
either by inhibiting endometrial receptivity or by blocking ovulation (51) (52) (53). The 
PRM Ulipristal was recently approved by the FDA for emergency contraceptive use. 
Given the substantial incidence of breast cancer, PRMs may confer major health 
benefits when used for indications including leiomyoma, or contraception. 
5.2 COMMENTS ON MATERIALS AND METHODOLOGY 
5.2.1 Study design 
Only three previously published studies on leiomyoma regression by mifepristone 
treatment were placebo controlled. The lack of placebo control is rather understandable, 
as 3 months-or longer, without relief from bleeding and other symptoms with a placebo 
treatment, could limit the number of patients available to participate in clinical trials. 
Although recruitment was slow in the present study, only one patient in the placebo 
group discontinued the study for prompt surgical treatment due to unacceptable 
bleeding. 
At the end of the study, some patients in the mifepristone treated group asked for 
continuation of the medication instead of surgery. It would be interesting to include 
such an option for the patients to choose in the protocol for future studies. 
5.2.2 Breast biopsies 
In the present and many previous studies on normal breast tissue, FNA is the method of 
choice. Repeat biopsies were frequently obtained without excessive discomfort for the 
patients. However, in about 50% of repeated biopsies the procuration of MECs were 
not obtained in sufficient number (>50 cells) to obtain a valid index for breast cell 
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proliferation. The 50% reduction in valid outcomes should be considered in future 
studies when calculating sample size.  
5.2.3 Tools for symptom registration and monitoring 
In the present study registration of leiomyoma derived symptoms did not disclose any 
significant findings with the exception of complete cessation of vaginal bleeding.  
Among general effects there was a small increase in the number of hot flushes 
recorded. No impact was found on pain, pelvic sense of heaviness or dysuria elicited by 
bladder pressure. However, patients with severe mechanical symptoms were less likely 
to accept participation in this study. Moreover, obvious risks of serious discomfort for 
the patient, or threat to pelvic organ function were criteria for exclusion of patients 
from the study. The patients not included due to severe symptoms at baseline reduced 
the inherent potential for dramatic reduction of mechanical symptom scores during the 
way of the study.A less blunt tool for evaluation of symptoms could add value for 
future studies. At the time of planning this study, to our knowledge, no validated tool 
for symptom self registration was available. Since then, the Uterine Fibroid Score- 
Quality Of Life questionnaire (UFS-QOL) has been developed. This questionnaire 
includes a number of validated questions which are actually similar to the questionnaire 
we used, (54). 
5.2.4 Diagnostic issues with leiomyomas   
Reduction of total uterine volume has been observed by other investigators. We agree 
with reports that ultrasound volumetric measurement has shown limitations in terms of 
accurately evaluating larger (>375 ml) and multiple (>4) leiomyomas (19, 55). In the 
present study the number of myomas was in the range of 1-4 for both treatment groups. 
The volume of all leiomyomas was calculated with the formula for an ellipsoid.  
However the total uterine volume cannot be considered ellipsoid, when multiple or 
larger leiomyomas were included. We therefore decided to exclude this parameter. 
Furthermore, it proved impossible to tag individual tumors. For this reason, in cases 
with multiple tumors, it was difficult to follow individual myomas between 
observations at 4 week intervals. Instead we restricted the measurements to the volume 
of the dominant leiomyoma and the sum volume of all others, up to 5, in each woman. 
With regard to the description of multiple leiomyomas, the lack of overview limits the 
accuracy of the vaginal probe compared to MRI. Dependence on observer experience is 
less with MRI than any of the ultrasound dependent investigation modalities, such as 
TVS or hydrosonography, as well as compared to hysteroscopy (55). MRI may be a 
better tool for reproducibility and mapping for scientific purposes. To study 
hemodynamic parameters, the use of ultrasound Doppler is considered superior, as no 
validated method for measuring blood flow and impedance is currently available with 
MRI. Our methods could not reveal any significant decrease in blood perfusion as an 
explanation for reduced bleeding and myoma regression. PI and peak flow was 
unchanged after mifepristone treatment within the group, or between groups at the end 
of study. The hemodynamic data showed pronounced variation within groups over time 
and between groups at the end of study.  
5.2.5 Leiomyoma IHC 
The cellular mitotic index is normally low in benign uterine leiomyomas. The PR 
receptor content is higher in leiomyoma than in the adjacent myometrium. The degree 
of proliferation is dependent on the menstrual cycle, with a marked increase of Ki-67 
during the secretory phase; markers for apoptosis are normally absent (56). By analogy, 
in the present study a significantly reduced proliferation as measured by Ki-67 
expression was found, and there was no increase of the apoptotic index as assessed by 
TUNEL analysis following exposure to mifepristone. 
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5.2.5.1 Steroid receptors and growth factors 
 The IRS scores on myoma tissue sections did not correlate well between the observers 
as the appearance of staining intensity varied in the sections according the plan of cut 
through the whorled tissue bundles. There was no difference in immunoreactivity 
between treatments, with the exception of ERα in the obliquely cut category. Nuclear 
receptors may be suitable for evaluation, but this is still difficult because of the multi 
directional arrangement of muscle and fibroblast bundles. Some cells are cross cut, 
potentially leaving behind a larger portion of nuclear material for staining and other 
tissue bundles exclude more of the nuclear substance by an oblique or tangential cut 
line. A 1.4 fold IRS over reactivity for cross cut bundles was seen similarly by both 
assessors. 
5.2.6 Mifepristone dosage 
We used a dose of 50 mg every other day which, due to the long half life of 
mifepristone should correspond to approximately 25 mg per day.  It is likely that the 
dose could be reduced by 2-5 times and still retain the positive effects on bleeding and 
leiomyoma volume regression (57) (58). A lower dose may give even fewer vasomotor 
effects. The dose required for an antiproliferative effect on the breast and endometrium 
is not known. Lower doses of 2-5 mg daily have recently been applied to contraception 
and leiomyoma treatment. 
 A 12 month study on 10 mg and 5 mg, gave 50% volume reduction and 60% 
amenorrhea after 6 months.  
 A 10 % occurrence of what was reported as "endometrial hyperplasia” was 
present only in the 10 mg cohort.  
 No further change occurred during the following 6 months.  
 Follow up, during 6 months after cessation of treatment, showed a maintenance 
of uterine volume reduction of 40% less than baseline, 8 out of nine cases had 
resumed menstrual bleeding, all had normal FSH values (58).  
Studies on daily doses of 2.5-5 mg of mifepristone, report 7% flushes and around 50% 
presence of endometrial cystic glandular dilatation without atypia (29, 59).  
To what degree patients would prefer amenorrhea is not known. If bleeding were 
regarded as acceptable, an even lower dose would be likely to marginalize the side 
effects.  
A higher dose, 50 mg daily, was used for a 6 month treatment of endometriosis and 
conferred endometrial changes with over expression of mitotic activity in stroma (60). 
In a case report from treatment of Mb Cushing, mifepristone 200 mg daily was 
administered. It was reported that the woman developed massive endometrial 
hyperplasia which was though reversible (61). It appears, thus, that the dose is crucial 
for the endometrium effect.  
5.3 PREVIOUS REPORTS 
Merging data from 384 cases, (Table II), a mean dose of 14 mg would give:  
 40% reduction of leiomyoma volume and amenorrhea in 90 % of cases after 
three months, and in 50% of cases after 6 months.  
 Pain relief would be accomplished in 6/10 cases.  
 Occurrence of hot flushes in 3/10 cases accompanied by endometrial "non 
physiological secretory changes” would be seen in 10% of cases.  
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5.4 MIFEPRISTONE AND THE BREAST  
5.4.1 The normal breast 
Studies on the clinical effects in normal breast tissue during long-term treatment with 
mifepristone are of interest. They contribute to the knowledgebase necessary for 
expanding the clinical applications of antiprogestins to contraception and in the 
treatment of leiomyoma and endometriosis. The lack of clinical data further justified an 
effort to gather information about the proliferation in MECs during mifepristone 
exposure. A significant reduction in MEC proliferation was found in this study.  
It has previously been shown that it is feasible to evaluate cell proliferation in FNA 
biopsy material from the breasts of post-menopausal women as well as from young, 
healthy women during the menstrual cycle, or from women on oral contraceptives. 
Data from these studies did not reveal any significant influence of age on breast 
15 reports 
18 studies                          
Table I 
Mifepristone treated cases (N=384), proportions after 3 and 6 months treatment, sorted 
after dosage. Eisinger reports a 12 month study with follow up. 18 studies, 15 reports, 2 
Chinese reports, from abstract in English. Sorted according to dose.  
Three studies are placebo controlled *.  
Year N                                
(Total 
384) 
Daily
dose 
(mg) 
Resid
ual  
leiom
yoma  
volum
e 
Amen
orrhe
a after 
3 
month 
Ame
norr
hea 
after 
6 
mon
th 
Pain 
relief 
Hot 
flashes 
Endomet 
Hyperpl 
 
Murphy 1995 9 50 
      
Murphy 1993 10 50 0.5 1.0 
  
0.4 
 
Engman * 2009 14 25 0.7 1.0 
 
0.0 0.4 0.0 
Murphy 1995 11 25 0.4 1.0 
    
Reinsch 1994 8 25 0.7 
   
0.0 
 
Yang(in Chinese) 1996 15 20 0.4 1.0  
1.0 0.7 
 
Zeng(in Chinese) 1998 45 12,5 0.8 1.0  
1.0 0.1 
 
Bagaria * 2009 19 10 0.7 0.8 
 
0.3 
 
0.6 
Carbonell 2008 49 10 0.8 0.9 
  
0.2 0.0 
Eisinger ut vol 2003 20 10 0.5 0.9 0.7 0.3 0.1 0.3 
Yang 1998 28 10 0.4 1.0 
 
1.0 0.7 
 
Murphy 1995 9 5 0.7 
     
Carbonell 2008 50 5 0.6 0.9 
  
0.1 0.0 
Fiscella ut vol* 2006 20 5 0.5  
0.4 
  
0.0 
Eisinger ut vol 2003 20 5 0.5 0.9 0.6 0.3 0.1 0.2 
Murphy  1995 9 5 0.7 1.0 
  
0.1 
 
Eisinger 12 months 2005 20 10 0.5  
0.6 
  
0.1 
Eisinger 12 months 2005 20 5 0.5  
0.6 
  
0 
Eisinger 2009 17 2,5 0.9 0.7 0.3 
  
0.0 
Mean 
  
13 0.6 0.9 0.5 0.6 0.3 0.1 
STDDEV 
   
0.1 0.1 0.1 0.4 0.3 0.2 
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epithelial proliferation. Furthermore, parity had no influence on the expression of Ki-
67. In previous studies on breast epithelium among naturally cycling women, the Ki-67 
index was 2.04% (range 0–6%) during the luteal phase. (50). A 4-fold up regulation 
during HT correlated to the estrogen levels, not the progestins used (49). In the context 
of oral contraception, a 2-fold increase in Ki-67 index premenopausal among combined 
oral contraceptive (COC) pill users was seen. The Ki-67 index correlated to the serum 
progesterone level of non users and to the level of levonorgestrel in COC users.  
Interestingly some women had a very high response rate of up to 50% positive for the 
Ki-67 index, and marked individual variation was registered among the oral 
contraceptive users (62).  
5.4.2 Cohort studies 
The Women´s Health Initiative study was closed prematurely as it was considered to 
disclose evidence for an elevated risk for breast cancer associated with the addition of 
progestins for HT. Furthermore, increased density on mammary X-rays was called into 
question our diagnostic tools for breast malignancy (63).  
Participants in the Breast Cancer Detection Demonstration Project (BCDDP) conducted 
between 1973 and 1980 were followed up until 1995 and 2082 breast cancers were 
identified among 46355 women. The relative risk was determined as1.2 for estrogen 
only and 1.4 for estrogen+progestin regimens. The yearly risk increase was 1 % for E2 
only, compared to 8% for E2+P4 regimens (64). 
5.4.3 In vitro studies 
Currently there is a lack of human in vivo clinical studies for treatment of breast cancer 
with mifepristone (65).  In MCF-7 cell lines mifepristone induced caspase activation 
and G1 arrest with or without combination with TMX, for TMX resistant or TMX 
responsive cell lines (66). On BRCA1 deleted mice, there is impaired metabolism of 
PR, conferring increased proliferation in MECs. This increase in proliferation was 
cancelled by mifepristone addition (67). For receptor negative MCF-7 cells the 
combination of TMX and mifepristone gave an additive effect compared to single 
therapy. An elevation of TGFβ was seen upon such combination treatment. TGFβ is a 
molecule which has potential importance for the treatment of receptor negative breast 
cancer (68). In summary, mifepristone mediates a protective, down regulatory effect on 
breast tissue proliferation.  
5.5 MIFEPRISTONE AND ENDOMETRIUM 
5.5.1  Progesterone receptor modulator Associated Endometrial 
Changes (PAECs) 
Endometrial effects of PRMs previously which have often previously been reported as 
"endometrial hyperplasia" have recently been modified and reviewed. The diagnostic 
criteria for PAEC are currently under development (69). Specific endometrial changes 
occur on treatment with PRMs. A mixed degree of proliferation and apoptotic changes 
are seen in specific, dilated cystic endometrial glands, with condensed stroma and 
perivascular thickening. In agreement with previous studies, specific cystic glandular 
dilatation and PAECs were observed in the present study. Earlier studies have reported 
that hyperplastic changes, seen in the endometrium, are reversible on discontinuation of 
treatment (61).  Progesterone and its receptor have a key position in determination of 
tissue and cell-cycle response to activated estrogen receptor; however mifepristone 
does not bind to ER. Continuous progesterone addition to estrogen is reported to exert a 
protective effect on the endometrium in a HT context (70). For PRMs a concern is 
directed towards the tentative endometrial proliferative effect. There is at present no 
evidence that bone demineralization or thrombembolism need to be taken into account 
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with PRM treatment. Nevertheless endometrial proliferation remains a concern, as 
blocking of the progesterone receptor leaves estrogen exposure unopposed.  
5.5.2 Antiproliferative effect in the endometrium 
Despite the potential of the therapy, concern has been raised about the effect of 
mifepristone, and other progesterone receptor antagonists, on the endometrium. 
Hypothetically, long-term treatment blocks the biological effects of progesterone, and 
could result in unopposed estrogenicity leading to endometrial hyperplasia and 
atypical changes. There is a growing body of evidence that PRMs exert an 
antiproliferative effect on the endometrium during the formation of specific cystic 
glandular dilatation. Reports describe suppression of ovulation and in the majority of 
cycles and asynchrony between endometrial and ovarian activity. After 120 days of 
treatment with two or 5 mg mifepristone daily no endometrial hyperplasia was seen, 
and markers of endometrial proliferation had decreased. Mitotic activity in glands and 
stroma was suppressed (71). In monkey studies, 30 days of daily 2 mg mifepristone, 
expression of Ki-67 and PCNA (Proliferating Cell Nuclear Antigen) indicated a cell 
cycle arrest in G1 as no mitoses were seen. Ki-67 and PCNA do not discriminate 
between cells arrested in G1 and cells actually included in proliferation (72). The 
present study may provide a basis for reduced concern about proliferation in the 
endometrium. It provides support for a protective effect of mifepristone on the 
endometrium. 
5.5.3 Androgen mediated effects 
The slight but significant increased levels of testosterone and androstenedione seen in 
the present study may be relevant to observed changes in endometrial morphology and 
induction of amenorrhea. Androgens inhibit endometrial proliferation. Increase of 
endometrial AR is seen with mifepristone treatment. Flutamide blocks AR and 
proliferation is no longer inhibited as shown in monkey studies. Treatment with the 
anti-androgen flutamide reversed several of the effects of progesterone antagonists on 
the endometrium which is strong evidence that AR is involved in the antiproliferative 
effect (73). In primates and women an up regulation in ARs was reported and a 
possible antiestrogen effect is thereby induced, leading to down regulation of 
endometrial proliferation as measured by an H3 (phosphorylated histone) mitosis 
marker (74) (75). Earlier studies showed that mifepristone bind to AR (Moguilewsky 
and Philibert, 1985). This was confirmed recently by studies on RBA (Relative Binding 
Affinity) to several steroid hormone receptors (76). The mechanism for increasing the 
androgen expression could be via a discrete activation of the pituitary-adrenal axis 
without obvious effect on the cortisol 24 h urinary excretion or alternatively by 
blocking endometrial aromatase activity. A direct inhibitory effect of mifepristone on 
endometrial aromatase activity in primary cell culture has been reported (77) and may 
have a role in the AR associated antiproliferative effect of mifepristone in the 
endometrium. 
5.5.4 Antioxidant effect 
In cell culture, a direct anti proliferative effect of mifepristone by inhibition of  
3
H-
thymidin incorporation was shown. However, this impact was dependent on the 
antioxidant properties of the molecule, at the 11-di- methyl amino-phenyl side chain, 
not the progesterone receptor targeting 17-prop-1-ynyl region of the mifepristone 
molecule (78). Reduction of the mifepristone molecule at C17 deletes its 
antiprogesterone but not its antioxidant properties. 
5.5.5 Effect on Uterovaginal bleeding  
The most promising and directly clinically useful effect of mifepristone may be the 
ability to promptly induce amenorrhea. HMB is often the reason for considering 
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surgical treatment. In the event of successful cessation of bleeding, the indication for 
surgery eventually declines. In our study no change in resistance or uterine blood flow 
was seen. A significant up regulation of micro vessels and GR (Glucocorticoid 
Receptors) in endometrial glands, and luminal epithelium was previously reported. 
Furthermore a down regulation of VEGF (Vascular Endothelial Growth Factor) in 
endometrial stroma was observed (79).  
5.6 GROWTH REGULATION OF LEIOMYOMAS 
In the present study the volume of the largest leiomyoma and the sum of all coexisting 
leiomyoma volumes were significantly reduced. Mifepristone treatment reduces the 
volume of uterine leiomyoma, but with pronounced individual variations. The strength 
of the present study is the the correlation of the in vivo treatment response in volume 
regression of uterine leiomyomas, to the gene expressions. 
Expression of the cytoplasmatic enzyme GSTM1 could hypothetically increase the 
effect of mifepristone for leiomyoma volume reduction, by reducing the expression of 
Reactive Oxygen Species (ROS), and increased metabolism of estrogens.  
In our study 8/12 women that had a leiomyoma volume regression of more than -20% 
were categorized as good responders while 4/12 with between -17 to +19%  volume 
change were categorized as poor responders. We found genes which significantly 
correlated to clinical myoma volume regression: PAK3, EFNB2 and PIK3C2G. Only 
PAK3 was significantly different between treatment groups in correlation to the 
percentual leiomyoma volume regression. 
The RTK ROR1 (+2, 5 fold) was positively correlated to TP53 (R=0, 89, p=0,019) 
which is associated with cellular down tuning and senescence, although the mechanism 
of action by which ROR1 exerts down tuning of the cell-cycle is not clear (see table VII 
and Fig.4 in paper IV). ROR1 is established as a Wnt protein frizzled receptor, and as 
such is tentatively involved in the Wnt pathway with tumor repressor activity (80) (81). 
Real time PCR confirmation showed for the mifepristone group, a + 3, 1 fold up 
regulation of the Wnt receptor tyrosine kinase ROR1. 
In a previous report, TP53 over expression, indicating apoptosis, led to senescence (82). 
In the present study, the effect of mifepristone treatment appears to be down regulated 
proliferation rather than up graded apoptosis, as indicated by results from TUNEL 
analysis.  
Down regulation of MKI67 gene expression, and decreased immunoreactivity of Ki-67 
in this study, could reflect leiomyoma cellular senescence (83). Significant down 
regulations were seen for PIK31(-2,9 fold), GRIN2A(-5,6 fold) and CREB5(-2,3 fold ) 
which are involved in submembranous induction of kinases, inducing Ras mediated 
cytoplasmatic MAPK cascades.  
5.6.1 Cytokines 
Most growth factor receptors are cytokine RTKs. The transduction of extracellular 
signaling to induction of intracellular signaling is activated through IGF-1/IGF-1R, 
FGF/FGFR, EGF/EGFR, PDGF/PDGF-R gene families that are involved in growth of 
uterine leiomyomas. Interestingly it was shown that P4 upregulated EGF and E2 EGF-
R. The expression of both hormones in cooperation was essential to mediate growth of 
leiomyoma cells in culture. Furthermore an up regulation of bcl-2 (apoptosis protector), 
and down tuning of TNF-alfa (apoptosis mediator), is consistent with a proliferative net 
response in leiomyoma to progesterone exposure (34). Also an inhibitory effect on 
IGF-1 m- RNA by P4 but not E2 is seen, down tuning the proliferative activity, 
indicating a dual effect of P4, depending on the local tissue composition and menstrual 
phase. The IGF-1R expression was unaffected by either P4 or E2 exposure. Multiple 
mutually dependent inputs on timing and tissue abundance, for the induction of 
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proliferation may give clues as to why certain leiomyomas grow during pregnancy and 
others do not.  
5.6.2 Treatment selectivity 
The PRM CDB2914 was observed to increase apoptosis and inhibit proliferation in 
leiomyoma cell cultures, but not in cells originating from adjacent myometrium. 
Cleaved Caspase 3 expression was upregulated and bcl-2 was downregulated in 
leiomyoma cells by CDB2914 exposure. Furthermore the expression of VEGF 
(Vascular Endothelial Growth Factor) was down regulated in myoma tissue, but not in 
adjacent myometrium (84), indicating a useful tumor vascular selectivity of CDB 2914. 
5.7 MEDICAL OR SURGICAL MANAGEMENT OF LEIOMYOMA 
Problems related to uterine leiomyoma cause a huge request for treatment and demand 
on resources which involve both the individual women affected and society as a whole. 
5.7.1 Surgical treatment 
Surgical treatment of uterine leiomyomas, whether more or less invasive, have for more 
than a century offered an option to address clinical problems related to uterine 
leiomyoma and have the advantages both of tradition and established methodology.  
For hysterectomy with benign indication, a report was compiled from 42 different 
clinics in Sweden. The proportion of severe complications reported by all participating 
clinics was mean (interclinic variation); 5% (0-13%) and mild complications was 23% 
(13-47) (85). Thus, this demonstrates that there is room for a shift in the paradigm 
towards medical options. 
5.7.2 Medical treatment 
Uterine leiomyoma growth is dependent on response evoking signaling from steroid 
hormones, mainly estrogen and progesterone. Manipulation of cellular receptors for 
steroid hormones is therefore a logical target for pharmacological interaction. PRMs are 
suggested in the context of several gynecological applications with hormonal 
dependence, such as fertility regulation, contraception, uterine leiomyoma and 
endometriosis. Clinical investigations in women confirming the potential benefits for 
long term treatment with no adverse effects on bone mineral density and with preserved 
level of serum estradiol were reported since 1993 (51, 86, 87) as well as research on 
cynomologous maquaques(88). When the present RCT was planned no placebo 
controlled studies were available.  
In the present study we limited the study duration to 12 weeks in order to provide a 
background for further studies with options for dose reduction and extended time 
periods as required for the treatment of uterine leiomyoma and endometriosis. With the 
aim of avoiding surgical treatment during the premenopausal years when increasing 
symptomatic prevalence develops,  symptomatic neutralization of uterine leiomyoma 
may be indicated between the ages of 40- 50, until natural menopause. Routine 
gynecological examination, cervical PAP smear, ultrasonographic examination, 
mammography and endometrial biopsy should be regarded as indispensable before 
initiation of treatment, with yearly follow up. 
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5.8 FUTURE PROSPECTS 
 
 PRMs are considered useful for the treatment of leiomyoma and endometriosis 
in premenopausal women apart from their usage for contraception. Application 
in postmenopausal HT could also be foreseen.  
 
 Further monitoring and research concerning the effects of mifepristone on 
endometrium and breast tissue is needed, although available data suggests a 
protective effect on breast tissue and an absence of harmful effects in the 
endometrium. 
 
 In order to study the molecular mechanism of action of mifepristone at protein 
level in leiomyoma, highly sensitive quantitation techniques are necessary. We 
plan to apply proximity ligase protein assay for this task. 
 
 Protein correlations to leiomyoma volume change in vivo could be relevant and 
helpful for understanding the molecular regulation of leiomyoma senescence. 
This could be explored in order to identify future therapeutic targets for 
leiomyoma. 
 
 Development of GSTM1 as a biomarker for the tailoring of medical treatment 
of uterine leiomyoma would include clinical trials and investigation of the 
possibility of developing a blood biochemical test suitable for the detection of 
GSTM1 expression. 
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6 CONCLUSIONS 
 
 Mifepristone treatment is appropriate for preoperative treatment of leiomyomas.  
During the treatment patients were free from vaginal bleeding, significantly 
avoiding the disadvantage of anemia at surgery.  
 
 A novel and important finding is the absence of increased proliferative 
development in breast tissue during treatment. Whether this effect would indeed 
lower the risk for breast cancer development during antiprogestin treatment 
remains to be shown. 
 
 Endometrial changes like PAEC are expected with low dose PRMs, though 
signs of proliferation are absent. 
 
 A down regulation of the phosphoinositide kinase regulating protein PIK3R1, 
involved in the initiation of Ras signaling and MAPK cascade activation, was 
seen following mifepristone exposure.  
 
 Involvement of PAK3 gene expression correlated to the clinical leiomyoma 
volume regression. PAK3 was characterized as a responder to 
antiglucocorticoid properties of mifepristone by cell culture experiment. 
 
 Determinants of the leiomyoma volume regression response to treatment may 
be associated to glutathione and Nrf pathways which are involved in quenching 
the effects of ROS, inducing down regulation of cell cycle progression in 
leiomyomas. 
 
 The objective of the medical community should be to provide effective and safe 
long term neutralization of leiomyoma symptoms, especially uterovaginal 
bleeding, although not necessarily removal of leiomyomas.  
 
 The introduction of PRMs for treatment of leiomyomas which interfere with the 
quality of life for women in their fertile age, may have substantial importance 
for the improvement of women‟s health in the near future.  
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